Mid-season influenza vaccine effectiveness (VE) was estimated using data from surveillance conducted by the Department of Defense Global, Laboratory-based, Influenza Surveillance Program at the United States Air Force School of Aerospace Medicine. Respiratory specimens from geographically diverse military members and dependents who sought medical care 2 October 2011-3 March 2012 were analyzed by viral culture and real-time reverse transcriptase-polymerase chain reaction; influenza viruses were typed and sequenced. Controls were influenza test-negative. Overall, vaccine type and subtype-specific VE were estimated using logistic regression. Adjusted VE (95% confidence interval) was: overall 77 (57-87)%; live attenuated vaccine (LAIV) 74 (48-87)%; trivalent inactivated vaccine (TIV) 75 (48-88)%. H3 component-specific VE was: overall 77 (52-89)%; LAIV 78 (47-91)%; TIV 74 (38-89)%; data were insufficient for separate H1 and B estimates. Both vaccine types showed moderate to high VE, indicating significant protection against circulating influenza strains.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.vaccine.2013.01.022 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Mid-season influenza vaccine effectiveness estimates among DOD populations: a composite of data presented at VRBPAC-the Vaccines and Related Biological Products Advisory Committee-2024 meeting on influenza vaccine strain selection for the 2024-2025 influenza season.
MSMR
March 2024
Global Emerging Infections Surveillance Branch, Defense Centers for Public Health-Dayton, Armed Forces Health Surveillance Division, Defense Health Agency.
2023/24 mid-season influenza and Omicron XBB.1.5 vaccine effectiveness estimates from the Canadian Sentinel Practitioner Surveillance Network (SPSN).
Euro Surveill
February 2024
National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Canada.
The Canadian Sentinel Practitioner Surveillance Network reports mid-season 2023/24 influenza vaccine effectiveness (VE) of 63% (95% CI: 51-72) against influenza A(H1N1)pdm09, lower for clade 5a.2a.1 (56%; 95% CI: 33-71) than clade 5a.
View Article and Find Full Text PDFNational influenza mid-season report, 2022-2023: A rapid and early epidemic onset.
Can Commun Dis Rep
January 2023
Centre for Immunization and Respiratory Infectious Diseases, Public Health Agency of Canada, Ottawa, ON.
Canada's 2022-2023 national influenza epidemic was declared in epidemiological week 43 (week ending October 29, 2022), relatively early in comparison to historical seasons. This year marks the return to pre-pandemic-like influenza circulation, following the brief and delayed influenza epidemic declared in the spring of the 2021-2022 season. To date this season, 59,459 detections of influenza have been reported out of 456,536 tests; both values exceeding historical averages.
View Article and Find Full Text PDFCan a Two-Dose Influenza Vaccine Regimen Better Protect Older Adults? An Agent-Based Modeling Study.
Vaccines (Basel)
October 2022
Department of Family Medicine, School of Medicine, University of Pittsburgh, Schenley Place, 5th Floor, Suite 520, Pittsburgh, PA 15260, USA.
Older adults (age ≥ 65) are at high risk of influenza morbidity and mortality. This study evaluated the impact of a hypothetical two-dose influenza vaccine regimen per season to reduce symptomatic flu cases by providing preseason (first dose) and mid-season (second dose) protection to offset waning vaccine effectiveness (VE). The Framework for Reconstructing Epidemiological Dynamics (FRED), an agent-based modeling platform, was used to compare typical one-dose vaccination to a two-dose vaccination strategy.
View Article and Find Full Text PDFNational FluWatch mid-season report, 2021-2022: Sporadic influenza activity returns.
Can Commun Dis Rep
January 2022
National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB.
Article Synopsis
- - Surveillance for the 2021-2022 seasonal influenza in Canada began in late August 2021 amidst the ongoing COVID-19 pandemic, with some influenza activity returning, including hospitalizations, but no confirmed outbreaks as of January 1, 2022.
- - A total of 429 sporadic influenza cases were reported across multiple provinces, with nearly half of the cases occurring in children under 19 and most detections being of influenza A, specifically A(H3N2).
- - Most strains identified were seasonal, with only one strain matching the 2021-2022 vaccine recommendations; all strains were sensitive to antiviral medications, indicating effective treatment options available.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!